Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Air Products & Chemicals, Inc.APD · Entity 2983 | Director | September 30, 2020 | October 01, 2020 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2023 | May 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Air Products & Chemicals, Inc.
Report date September 30, 2020 · Filed October 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 42,813.6292 |
Reported balance
After 2020-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-30 · Grant · Acquired 194.3437 · Balance 42,813.6292 F1: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan. F2: Not applicable to this security F3: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. |
Filing footnotes · ownership attribution and instrument terms
F1: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, under the Company's Long-Term Incentive Plan.
F2: Not applicable to this security
F3: These Units are payable in the form of shares of common stock equal in number to the Units, at the time elected by the reporting person, which is generally after service on the Company's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance.
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,468 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 44,468 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2023 · Filed May 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $342.73 · Expires 2033-04-30 | Direct | 3,481 |
Reported balance
After 2023-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-01 · Grant · Acquired 3,481 · Balance 3,481 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 1
1 source rowRow 1 · 2026-04-27 · Disposition to issuer · Disposed 94,631 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 31,000 shares of Common Stock and 63,631 restricted stock units (which vested in full in connection with consummation of the Merger). |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 31,000 shares of Common Stock and 63,631 restricted stock units (which vested in full in connection with consummation of the Merger).
F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3: Each Option was fully vested.
F4: Each Option vested in full in connection with consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2017 Filed Jan 27, 2017 18:06 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 807 | $148.81 Strike: $0.00 | $120,089.67 |
DisclosureSEC source: 0001225208-17-001834 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,022.6873 Underlying: Common Stock · 807 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 19:27 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 189.7897 | $145.12 Strike: $0.00 | $27,542.28 |
DisclosureSEC source: 0001225208-17-000269 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,215.6873 Underlying: Common Stock · 189.7897 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| September 30, 2016 Filed Sep 30, 2016 17:17 UTC | Air Products & Chemicals, Inc. APD · Entity 2983 | GrantPhantom Stock · Derivative | 182.8351 | $149.78 Strike: $0.00 | $27,385.04 |
DisclosureSEC source: 0001225208-16-039777 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,025.8976 Underlying: Common Stock · 182.8351 shares Expires not disclosed F1 · security: Phantom deferred stock units (Units) acquired under the Air Products Stock Account of the issuer's Deferred Compensation Program for Directors, of the Company's Long-Term Incentive Plan (the Plan). F2 · derivative.exercise_price: Not applicable to this security F3 · derivative.exercise_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. F3 · derivative.expiration_date: These units are payable in the form of shares of common Stock equal in number to the units, at the time elected by the reporting person, which is generally after service on the issuer's Board of Directors ends. Units may be paid in a lump sum or up to ten installments as elected by the reporting person in advance. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 7,073 | $0.00 Strike: $93.51 | $0.00 |
DisclosureSEC source: 0001209191-16-125718 · doc4.xml · derivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,073 Underlying: Common Stock · 7,073 shares Expires 2026-05-31 F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2016 Filed Jun 3, 2016 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,941 | $0.01 | $29.41 |
DisclosureSEC source: 0001209191-16-125718 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,029 F1 · shares: Restricted stock unit award that vests on the first anniversary of the grant date. Read SEC document |
| November 18, 2015 Filed Nov 20, 2015 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-15-081520 · doc4.xml · derivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| November 18, 2015 Filed Nov 20, 2015 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,500 | $130.15 | $1,626,875.00 |
DisclosureSEC source: 0001209191-15-081520 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $130.15 (range $130.00 to $130.55). F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 18, 2015 Filed Nov 20, 2015 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,500 | $57.27 | $715,875.00 |
DisclosureSEC source: 0001209191-15-081520 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2015 Filed Aug 5, 2015 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-15-064024 · doc4.xml · derivative · entry 6 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| August 03, 2015 Filed Aug 5, 2015 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $138.98 | $13,898.00 |
DisclosureSEC source: 0001209191-15-064024 · doc4.xml · nonDerivative · entry 5 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 03, 2015 Filed Aug 5, 2015 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,700 | $138.22 | $373,194.00 |
DisclosureSEC source: 0001209191-15-064024 · doc4.xml · nonDerivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,188 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $138.22 (range $137.94 to $138.92). Read SEC document |
| August 03, 2015 Filed Aug 5, 2015 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,500 | $137.26 | $892,190.00 |
DisclosureSEC source: 0001209191-15-064024 · doc4.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,888 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $137.26 (range $136.91 to $137.90). Read SEC document |
| August 03, 2015 Filed Aug 5, 2015 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,200 | $136.49 | $436,768.00 |
DisclosureSEC source: 0001209191-15-064024 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,388 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $136.49 (range $135.89 to $136.88). F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2015 Filed Aug 5, 2015 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,500 | $57.27 | $715,875.00 |
DisclosureSEC source: 0001209191-15-064024 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $53.85 | $0.00 |
DisclosureSEC source: 0001209191-15-049569 · doc4.xml · derivative · entry 7 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2021-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-15-049569 · doc4.xml · derivative · entry 6 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 5,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $127.54 | $0.00 |
DisclosureSEC source: 0001209191-15-049569 · doc4.xml · derivative · entry 5 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-05-31 F5 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,020 | $127.53 | $1,150,320.60 |
DisclosureSEC source: 0001209191-15-049569 · doc4.xml · nonDerivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $127.53 (range $127.11 to $128.05). Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,480 | $126.78 | $441,194.40 |
DisclosureSEC source: 0001209191-15-049569 · doc4.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,108 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $126.78 (range $126.11 to $127.07). F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $53.85 | $403,875.00 |
DisclosureSEC source: 0001209191-15-049569 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 5,000 | $57.27 | $286,350.00 |
DisclosureSEC source: 0001209191-15-049569 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2015 Filed Apr 8, 2015 23:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 12,500 | $0.00 Strike: $53.85 | $0.00 |
DisclosureSEC source: 0001209191-15-033248 · doc4.xml · derivative · entry 6 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 12,500 shares Expires 2021-05-31 F7 · derivative.exercise_date: Fully vested. Read SEC document |
| April 06, 2015 Filed Apr 8, 2015 23:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $119.78 | $47,912.00 |
DisclosureSEC source: 0001209191-15-033248 · doc4.xml · nonDerivative · entry 5 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $119.78 (range $119.72 to $119.95). Read SEC document |
| April 06, 2015 Filed Apr 8, 2015 23:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,900 | $118.97 | $463,983.00 |
DisclosureSEC source: 0001209191-15-033248 · doc4.xml · nonDerivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,488 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $118.97 (range $118.64 to $119.58). Read SEC document |
| April 06, 2015 Filed Apr 8, 2015 23:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,000 | $118.32 | $709,920.00 |
DisclosureSEC source: 0001209191-15-033248 · doc4.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,388 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $118.32 (range $117.64 to $118.63). Read SEC document |
| April 06, 2015 Filed Apr 8, 2015 23:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,200 | $117.14 | $257,708.00 |
DisclosureSEC source: 0001209191-15-033248 · doc4.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,388 F1 · kind: Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $117.14 (range $116.56 to $117.53). F3 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 06, 2015 Filed Apr 8, 2015 23:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,500 | $53.85 | $673,125.00 |
DisclosureSEC source: 0001209191-15-033248 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2014 Filed Jun 3, 2014 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-14-038663 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2024-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 01, 2013 Filed Jun 4, 2013 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0001209191-13-030494 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| November 07, 2012 Filed Nov 8, 2012 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 1,000 | $45.50 | $45,500.00 |
DisclosureSEC source: 0001209191-12-052295 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · price: Open market purchases reported on this line occurred at a weighted average price of $45.50 (range $45.22 to $45.71). F2 · price: Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 10, 2012 Filed Feb 13, 2015 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 15 | $51.23 | $768.45 |
DisclosureSEC source: 0001209191-15-013522 · doc5.xml · nonDerivative · entry 4 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · balance_after: As of 12/31/2014. Read SEC document |
| June 01, 2012 Filed Jun 1, 2012 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-12-031709 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2022-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| December 07, 2011 Filed Feb 13, 2015 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 9 | $29.19 | $262.71 |
DisclosureSEC source: 0001209191-15-013522 · doc5.xml · nonDerivative · entry 3 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · balance_after: As of 12/31/2014. Read SEC document |
| December 06, 2011 Filed Feb 13, 2015 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 33 | $29.66 | $978.78 |
DisclosureSEC source: 0001209191-15-013522 · doc5.xml · nonDerivative · entry 2 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · balance_after: As of 12/31/2014. Read SEC document |
| November 22, 2011 Filed Feb 13, 2015 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 31 | $28.00 | $868.00 |
DisclosureSEC source: 0001209191-15-013522 · doc5.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 F1 · balance_after: As of 12/31/2014. Read SEC document |
| June 01, 2011 Filed Jun 2, 2011 20:42 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $53.85 | $0.00 |
DisclosureSEC source: 0001209191-11-032541 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2021-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 12, 2011 Filed May 13, 2011 18:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $57.27 | $0.00 |
DisclosureSEC source: 0001209191-11-028289 · doc4.xml · derivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2021-05-11 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan vesting in 16 quarterly installments from 05/12/2011. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.